Random Recall Part 2 Flashcards
Vascular calcification’s greatest risk factor
Low bone turnover/Adynamic Bone disease
What is feared using 0 K Bath/Low K Bath
Arrhythmia
Most dreaded complication of Acquired Polycystic Kidney Disease
Malignancy
Other Treatment option for APKD proven by studies that can dec. cyst size/vol
Tolvaptan
uremic toxin is attributed to platelet dysfunction
Guanidosuccinic Acid
most common stimulus for PTH release
decrease in Calcium
imaging to rule out ADPKD having infection
FDG PET
Hallmark of renal disease progression
Proteinuria
Hypokalemia, Low rennin, Low aldo, HTN, Met Alkalosis
LIDDLE’s Syndrome
only urinary findings with Acetazolamide
Bicarbonaturia
Treatment of NDI, antihyperglycemic agent
Chlorpropramide
Mechanism of hyperkalemia sec. to Trimethroprim
Blocks ENAC
MC cause of hypermagnesemia
Renal Insufficiency
PTH Localization pre op
Sestamibi scan
Most Common form of Calcium in the blood
Free Ionized Ca
GN Associated with NSAID use
MCD
treatment to MN
Ponticelli Protocol
Management of AntiGBM Disease
Plasmapheresis+Steroids+Cyclophosphamide
minimal mesangial stain for C3 IgM and effacement of foot process on EM
MCD
Most common cause of RPGN in adult
Pauci Immune Crescentic GN
supepithelial hump deposits
PSGN
subepithelial deposits
MN
cause of hematuria in Sickle cell nephropathy
Microinfarcts in the medulla
Agent Causing collapsing FSGS
Pamidronate
steroid resistant FSGS treatment
Cyclosporine
Type of FSGS behaves like MCD with sudden/abrupt proteinuria
Tip lesion FSGS
Treatment for C3GN
MMF+ Rituximab
Synpharyngitic hematuria
IgAN
GN patient is morbidly obese
FSGS (Perihilar Type
feature of IgAN with better prognosis
macroscopic hematuria
fluid of choice to test if prerenal responsive vs. HRS
Human Albumin 25%
is combined with large volume paracentesis
Human Albumin 25%
agent that causes AKI by TMA
Bevacizumab
Drug causing AKI that causes precipitation of Crystals
Methotrexate
Novel AKI biomarker that assist in repair of renal tubules and decreases apoptosis
NGAL
RRT of choice IN Tumor lysis Syndrome
Intermittent HD
Treatment of AKI with volume overload
Furosemide
protein requirement of a given patient,AKI on RRT
1-1.3
protein requirement of a given patient,AKI on CRRT
1.7 g/kg
Inflammatory cell seen earliest in Ichemic Injury/AKI
neutrophil
Endothelial phenomenon that result to reduction of blood vessel density following ischemic injury
Vascular drop out
Mechanism of AKI induced by NSAIDs
vasoconstriction
mechanism of AKI in CIN
direct tubular toxicity
mechanism of NAC
depleting glutathione
post cardiac procedure, with livedo reticularis, elevated crea, oligoanuria)
atheroemboli